Mineralys Therapeutics, Inc. (MLYS): R&D Expense
$132.01M
Year ended 2025-12-31
$301.59M
Trailing 12 months to 2026-06-30
+71.3%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $132.01M | -21.7% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $168.58M | +139.6% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $70.36M | +168.0% | 2025-02-12, From 2023-01-01 |
| 2022-12-31 | $26.25M | n/a | 2024-03-21, From 2022-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | 2025-12-31 | $132.01M | -21.7% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $159.29M | +15.3% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $19.81M | -5.1% |
| Immunome Inc. (IMNM) | 2025-12-31 | $177.29M | +36.9% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $182.78M | +14.5% |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $316.90M | +43.0% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $183.28M | -2.0% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $300.94M | +43.0% |
| Viking Therapeutics, Inc. (VKTX) | 2025-12-31 | $344.95M | +239.4% |
Compare MLYS, PTGX, AMRN, IMNM side by side · Screen every company in Pharmaceutical Preparations ↗